Related Experiment Video
Updated: May 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Integrase Inhibitors: Redefining HIV-1 Treatment and Future Challenges
1Associate Research Professor in the Department of Microbiology and Molecular Immunology, at Saint Louis University School of Medicine, St. Louis, Missouri, USA.
The discovery and development of HIV-1 integrase strand transfer inhibitors (INSTIs) represent one of the remarkable success stories in antiviral drug discovery, transforming fundamental insights of retroviral enzymology into highly effective first-line therapies for HIV-1/AIDS patients. Currently there are five INSTIs approved for clinical use. Among these, second generation drugs Dolutegravir, Bictegravir and Cabotegravir offer excellent virologic suppression, favorable tolerability and a high genetic barrier to resistance. The long-acting formulation of the most recent INSTI Cabotegravir has also been approved for pre-exposure prophylaxis in high-risk populations. Apart from inhibiting the active site of integrase, a new class of allosteric integrase inhibitors (ALLINIs), which target integrase multimerization affecting multiple steps in viral life cycle, are in the advanced phases of clinical trials. The mechanisms of HIV-1 integration, development of integrase inhibitors, structural biology breakthroughs that guided inhibitor optimization and clinical use of INSTIs, their successes and challenges for HIV/1AIDS management are reviewed here.
The discovery and development of HIV-1 integrase strand transfer inhibitors (INSTIs) represent one of the remarkable success stories in antiviral drug discovery, transforming fundamental insights of retroviral enzymology into highly effective first-line therapies for HIV-1/AIDS patients. Currently there are five INSTIs approved for clinical use. Among these, second generation drugs Dolutegravir, Bictegravir and Cabotegravir offer excellent virologic suppression, favorable tolerability and a high genetic barrier to resistance. The long-acting formulation of the most recent INSTI Cabotegravir has also been approved for pre-exposure prophylaxis in high-risk populations. Apart from inhibiting the active site of integrase, a new class of allosteric integrase inhibitors (ALLINIs), which target integrase multimerization affecting multiple steps in viral life cycle, are in the advanced phases of clinical trials. The mechanisms of HIV-1 integration, development of integrase inhibitors, structural biology breakthroughs that guided inhibitor optimization and clinical use of INSTIs, their successes and challenges for HIV/1AIDS management are reviewed here.
Related Concept Videos
Retrovirus Life Cycles
Size and Structure of Viral Genomes
Inhibitors of Viral Protein Synthesis
Retroviruses
Sexually Transmitted Infections
Viral Hepatitis I: Introduction

